Clinical Trial

Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At that time, the study will become open-label and all subjects will be placed on (or continue) vitamin D3 for an additional 12 weeks. The study will take place over 28 weeks total.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2019-07-25; most recent amendment 2026-02-17.
Status change: Not Yet Recruiting → Recruiting 2020-01-27
Trial Details
NCT Number NCT04036188
Lead Sponsor Wright State University
Conditions Plaque Psoriasis, Vitamin D3
Enrollment 24 participants
Start Date 2019-10-16
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-19